TEL AVIV, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3rd Annual Healthcare Day.
| Jefferies 2016 Healthcare Conference | |||
| Date: | Wednesday, June 8 | ||
| Time: | 8:00am Eastern Daylight Time | ||
| Location: | Grand Hyatt Hotel, New York City | ||
| Webcast: | http://wsw.com/webcast/jeff97/adhd | ||
| ROTH 3rd Annual Healthcare Day | |||
| Date: | Wednesday, June 22 | ||
| Location: | The Dorchester Hotel, London UK | ||
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of MDX, a proprietary drug candidate, to treat cognitive disorders including ADHD and Fragile X. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.